Efficacy results (based on the intention-to-treat population)
| Variable | Topiramate (N = 14) | Placebo (N = 13) | p Value | CI |
| Mean TTS (baseline) | 26.64 (8.78) | 28.77 (7.53) | ||
| Mean TTS (visit 5) | 12.36 (12.04) | 23.10 (8.99) | −18.43 to −1.31 | |
| Mean change from baseline TTS (visit 5)* | −14.29 (10.47) | −5.00 (9.88) | 0.0259 | |
| Mean TMTS (baseline) | 13.93 (4.70) | 14.23 (4.21) | ||
| Mean TMTS (visit 5) | 8.14 (5.95) | 12.80 (6.63) | −9.02 to −0.02 | |
| Mean change from baseline TMTS (visit 5) | −5.79 (5.67) | −1.30 (4.35) | 0.0493 | |
| Mean TPTS (baseline) | 12.71 (5.36) | 14.54 (5.38) | ||
| Mean TPTS (visit 5) | 4.21 (6.72) | 10.30 (5.93) | −11.17 to −0.18 | |
| Mean change from baseline TPTS (visit 5) | −8.50 (6.10) | −3.70 (8.41) | 0.0435 | |
| Mean GSS (baseline) | 57.36 (20.04) | 58.00 (18.86) | ||
| Mean GSS (visit 5) | 20.21 (24.96) | 50.10 (18.08) | −47.94 to −11.21 | |
| Mean change from baseline GSS (visit 5) | −37.14 (24.73) | −8.00 (22.48) | 0.0030 |
*A component of the Yale Global Tic Severity Scale, the change from baseline in Total Tic Score (TTS) at visit 5 (day 70) is the predefined primary endpoint
GSS, Global Severity Score; TMTS, Total Motor Tic Score; TPTS, Total Phonic Tic Score.